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Abstract
Background: Prostate cancer cells communicate reciprocally with the stromal cells surrounding them, inside the
prostate, and after metastasis, within the bone. Each tissue secretes factors for interpretation by the other. One
stromally-derived factor, Hepatocyte Growth Factor (HGF), was found twenty years ago to regulate invasion and
growth of carcinoma cells. Working with the LNCaP prostate cancer progression model, we found that these
cells could respond to HGF stimulation, even in the absence of Met, the only known HGF receptor. The new
HGF binding partner we find on the cell surface may help to clarify conflicts in the past literature about Met
expression and HGF response in cancer cells.
Methods: We searched for Met or any HGF binding partner on the cells of the PC3 and LNCaP prostate cancer
cell models, using HGF immobilized on agarose beads. By using mass spectrometry analyses and sequencing we
have identified nucleolin protein as a novel HGF binding partner. Antibodies against nucleolin (or HGF) were able
to ameliorate the stimulatory effects of HGF on met-negative prostate cancer cells. Western blots, RT-PCR, and
immunohistochemistry were used to assess nucleolin levels during prostate cancer progression in both LNCaP
and PC3 models.
Results: We have identified HGF as a major signaling component of prostate stromal-conditioned media (SCM)
and have implicated the protein nucleolin in HGF signal reception by the LNCaP model prostate cancer cells.
Antibodies that silence either HGF (in SCM) or nucleolin (on the cell surfaces) eliminate the adhesion-stimulatory
effects of the SCM. Likewise, addition of purified HGF to control media mimics the action of SCM. C4-2, an
LNCaP lineage-derived, androgen-independent human prostate cancer cell line, responds to HGF in a
concentration-dependent manner by increasing its adhesion and reducing its migration on laminin substratum.
These HGF effects are not due to shifts in the expression levels of laminin-binding integrins, nor can they be linked
to expression of the known HGF receptor Met, as neither LNCaP nor clonally-derived C4-2 sub-line contain any
detectable Met protein. Even in the absence of Met, small GTPases are activated, linking HGF stimulation to
membrane protrusion and integrin activation. Membrane-localized nucelolin levels increase during cancer
progression, as modeled by both the PC3 and LNCaP prostate cancer progression cell lines.
Conclusion: We propose that cell surface localized nucleolin protein may function in these cells as a novel HGF
receptor. Membrane localized nucleolin binds heparin-bound growth factors (including HGF) and appears
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upregulated during prostate cancer progression. Antibodies against nucleolin are able to ameliorate the
stimulatory effects of HGF on met-negative prostate cancer cells. HGF-nucleolin interactions could be partially
responsible for the complexity of HGF responses and met expression reported in the literature.
Background
In the prostate, cell-matrix adhesion, cell motility and
invasive behaviors are regulated by an interplay of signals
between the epithelial cells and surrounding stromal cells
[1-6]. Signal reciprocity allows prostate stromal fibrob-
lasts to control epithelial cell proliferation [7], while epi-
thelial cells control such processes as stromal smooth
muscle maturation [8]. When signal reception or intercel-
lular signal interpretation alter adhesion-based behaviors,
tumor formation and cancer progression can result. Can-
cer cells are known to optimize their stromal growth envi-
ronments [6,9,10]. Indeed, the list of factors involved in
bi-directional epithelial-stromal cell interactions is long,
with representatives from many growth factor families,
and includes Hepatocyte Growth Factor (HGF) [11], a
subject of this study.
HGF regulates cell behaviors in organ development, tissue
regeneration and cancer [12-15]. HGF's source, reception
by, and effects on prostate cancer cells are discussed in
many review articles, as is the Met protein, the only
known cell surface receptor for HGF [16-21]. Once
secreted, it is likely that most HGF is immobilized within
the extracellular matrix of the stromal cells by binding
heparan sulfate proteoglycans [22-26]. HGF encounters
the Met receptor in the basal cells of the prostatic ducts
and acini, and in low numbers on the luminal cells of the
prostatic ducts and stromal smooth muscle cells [27-29].
During puberty, developing branches within the prostate
show high concentrations of Met in ductal tips and
respond to stromal stimulation [30,31], a hallmark for
HGF/Met-mediated activity. Met signaling is also critical
for ductal system formation in kidney, mammary gland,
liver, pancreas and lung [32-35]. High levels of Met
expression correlate with increased cell movement, and
indeed metastasis is linked to the uncontrolled branching
seen at earlier stages of prostate disease [36,37]. Further-
more, dysfunctional and high Met expression is found in
a variety of human cancers [38-41,21,42,43] and corre-
lates with some metastasis in animals [44,45].
Met expression levels during cancer progression remain
somewhat confusing, and conflicting reports are common
in the published literature. Met expression does appear to
increase during prostate disease progression, but the cor-
relation of Met expression with Gleason grade has been
tenuous. Approximately 50% of localized cancers (and
even more metastatic cancers) express Met [28,29,43,46].
In one study, Met elevations were found in 84% of local-
ized prostate cancers [29], but Humphry et al. [28]
reported that 45% of 108 cases show no correlation
between disease progression and Met expression; further,
the receptors in this study were localized by staining to
both the cell surface and the cytoplasm. There are two
other reports [43,46] of a clear increase in Met expression
correlating with higher grades of adenocarcinomas (with
metastases expressing more Met in bone than lymph node
[29]), but no correlation between Met expression and dis-
ease progression, in a 5-year follow up period [43]. Not
only are Met expression profiles not consistently linked to
disease outcome [21,42,43], but Met expression is also
confounding in the commonly-studied in vitro model sys-
tems. Met expression is higher in some metastatic prostate
cancer samples compared to less-progressed cells [47-49];
for example, met RNA and protein levels are elevated in
the androgen-independent cell lines DU145, PC3 and
PC3M, compared to androgen-dependent LNCaP cells
[27,28,43,50-54]. But, this correlation does not hold
within the LNCaP-derived cell lines themselves, since nei-
ther parental LNCaP nor its lineage-derived, androgen-
independent variant C4-2 actually express the HGF recep-
tor Met. Thus, although both HGF and Met are arguably
very important for prostate cancer progression, the details
of their functions remain far from clear.
Further complicating Met/HGF correlations and prostate
cancer models is the fact that high Met expression levels
do not always invoke concentration-dependent responses
to HGF treatment. For example, high-Met-expressing
DU145 prostate cancer cells showed concentration-
dependent responses to HGF, with increased cell motility
in both scatter and invasion assays, whereas PC3 cells
(with equally high levels of Met expression) did not
respond under the same conditions [28]. These, and other
contradictory reports of anti-apoptotic and pro-apoptotic
responses to HGF treatment, have led some investigators
to suggest that the lack of downstream signals explains
differences between cell types [55], or that these differ-
ences may be due to isoform variants of HGF and Met
themselves, or further that signaling pathway intermedi-
ates (such as PI3-kinase/Akt) may become saturated by
extra-cellular matrix adhesion [56-63] and can not further
be phosphorylated. We report here that cell adhesion to
extra-cellular matrix does appear to play a role in cell
spreading and migration response to HGF, as PC3 cells do
respond to HGF treatment under our serum containing
and starved growth conditions, but only when plated on
laminin substrata. We and others, have been unable toBMC Cancer 2006, 6:197 http://www.biomedcentral.com/1471-2407/6/197
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detect any Met expression in LNCaP and C4-2 cells at
either the protein or RNA levels (Figure 4; [21,43]), and
yet we find a clear concentration-dependent response to
HGF stimulation in these cells.
HGF likely acts through multiple isoforms, receptors and/
or signaling cascades to bring about a variety of cell
responses. Also called Scatter Factor (SF), HGF stimulates
motility in both endothelial and metastatic epithelial can-
cers [53,55,64,65], similar to the invasion-promoting fac-
tor plasminogen [19,66,67]. Not surprisingly, HGF levels
affect the function of prostate integrins [53,55], molecules
involved in cell adhesion and motility. In this study, we
have focused upon HGF's regulation of cell adhesive
behaviors in a collection of human prostate cancer cell
lines, including cell lines that do not express the Met
receptor for HGF, but nonetheless exhibit distinct, con-
centration-dependent responses to the growth factor and
to stromal-conditioned media (SCM). We previously
reported that SCM increased cell spreading in the meta-
static prostate cancer cell line C4-2, while having little
effect on attachment of the lineage-related, non-meta-
static LNCaP cell line [68]. We have now extended this
work, further identifying HGF as responsible for the
effects of SCM and describing HGF dose-dependent
effects on the adhesive behaviors of these cell lines. In
addition, we have especially searched for the responsible
HGF receptors in these cells, as we and others have found
both cell lines to lack the met protein, the one known
HGF receptor ([43] and this study). Here, we introduce
the protein nucleolin as a novel HGF binding partner in
prostate cancer cells. Nucleolin, an abundant nuclear pro-
tein [69,70], is also found on the cell surface, where it has
been shown to interact with heparin-bound growth fac-
tors [71-73], and where it functions as a cell surface recep-
tor and a shuttle protein for nuclear import [72,74-76].
Significantly, nucleolin is also currently the focus of a
phase II clinical trial as a cancer therapy target [77,78].
Methods
Cell culture and materials
Prostate epithelial and stromal cell lines were maintained
in T-media with 5% fetal bovine serum, at 37°C with 5%
CO2. Primary cultures of prostate stromal cells were
derived from the tissue surrounding prostatic adenocarci-
nomas, as described by Ozen et al. [79]. Conditioned
media were prepared by adding fresh media without
serum when cells reached 80% confluence and removing
it 48 h later. For signaling assays, cells were starved in
RPMI-1640 phenol red-free medium (Life Technologies,
Inc.) un-supplemented with serum. Laminin-1 (a kind gift
of Roy Ogle at the University of Virginia) was purified
from Engelbreth-Holme-Swarm (EHS) tumors according
to the method of Davis et al., based on the protocol of
Kleinman et al. [80,81]. Hepatocyte Growth Factor (HGF)
and all other chemicals were purchased from Sigma (St.
Louis, MO). Anti-FAK and HGF antibodies were from
Sigma (St. Louis, MO) and Santa Cruz Biotechnology
(Santa Cruz, CA). Antibodies to nucleolin were purchased
from Santa Cruz Biotechnology or received as a gift from
Dr. Deng at Pittsburgh Medical Center. Met antibodies, as
well as cdc-42 and Rac immuno-precipitation reagent
were purchased from both UpState Biotechnology (Lake
Placid, NY) and Transduction Laboratories (Lexington,
KY). Phospho-tyrosine antibodies were from Transduc-
tion Laboratories (Lexington, KY). Phospho-Akt (Ser 473)
antibody and Akt antibody were purchased from Cell Sig-
naling Technology Inc. (Beverly, MA). Anti-β actin anti-
body was from Abcam Inc. (Cambridge, MA). All
secondary-conjugated antibodies were from Jackson
Immunochemicals (West Grove, PA).
Semi-quantitative reverse transcription PCR
Total cellular RNA was isolated with RNA-STAT (BioTec-X,
Houston, TX). 5 μg of RNA was reverse transcribed using
the OmniScript RT Kit (Qiagen, Inc., Valencia, CA). The
primers used for met amplification were as follow: F-met
5'-GGTTGCTGATTTTGGTCAT-3' and B-met 5'-TTCG-
GGTTGTGGAGTCTT-3'.
Immunoprecipitation
Cells were allowed to grow to 80% confluency and then
serum starved for 48 hours. Plates were rinsed twice in ice-
cold phosphate buffered saline (PBS) and solubilized in
lysis buffer (1% NP-40, 50 mM Tris-HCl, 150 mM NaCl,
2 mM EDTA, 50 mg/ml leupeptin, 0.5% aprotinin, 1 mM
sodium orthovanadate, 1 mM PMSF). Insoluble material
was removed by centrifugation for 30 min at 10,000 × g at
4°C. Protein concentration was determined by BRC assay
(BioRad, Hercules, CA). 1–2 mg of protein was used for
each immunoprecipitation condition. Antibodies were
incubated with the cell lysate for 2 hrs at 4°C, and an
additional 30 min with Protein A/G-sepharose beads
(Sigma). The beads were washed three times with lysis
buffer and resuspended in SDS-PAGE loading buffer.
Samples were resolved on gradient (4–12%) or 10% poly-
acrylamide gels (Novex) and electro-blotted. After trans-
fer, the filters were blocked in BSA (5%) overnight at 4°C.
Filters were incubated with primary antibodies for 1 hr at
room temperature. Membranes were then probed for 1 hr
with peroxidase-conjugated secondary antibody (diluted
1:5000; Jackson Immunoresearch Labs, Bar Harbor, ME)
and the proteins were detected with Enhanced Chemi-
Luminescence (ECL)(Amersham Biosciences, Little Chal-
font, England).
Substrate adhesion and growth assay
Attachment assays were performed as previously
described in Edlund et al., and Vafa et al., [68,82]. Cell
lines were grown to confluence, trypsinized, and re-platedBMC Cancer 2006, 6:197 http://www.biomedcentral.com/1471-2407/6/197
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(1:8) on tissue culture dishes, where they were allowed to
grow for another two days before being lifted after a brief
treatment with 10 mM EDTA, 20 mM Hepes buffer in T-
media. After neutralizing the EDTA with CaCl2 and
MgSO4, the cells were washed with T-media containing
0.1% BSA. Cells were placed on laminin1-coated dishes,
allowed to adhere for 30 to 90 min with or without addi-
tion of either HGF or function blocking integrin antibod-
ies, and then fixed in para-formaldehyde (3.8%). The
percentage of spread cells was scored for each cell line,
based on cell membrane protrusion (lamellipodia and/or
filopodia), and all values were normalized to control cells
treated identically except for being subjected to condi-
tioned media or growth factors. This normalization step
was necessary because of the differences in speed of
attachment between the cell lines. Cell growth was quan-
tified using MTT [83,84].
ELISA detection of HGF
ELISAs were performed as suggested in Pharmigen
Research Products Catalog, 1999. Briefly, rabbit anti-
human HGF antibodies were diluted to a concentration of
1 μg/ml in 0.1 M Na2HPO4 and 0.1 M NaH2PO, pH 9.0.
Wells of a 96 well ELISA plate (Costar) were filled with 50
μl, sealed with parafilm, and incubated overnight at 4°C.
Plates were then brought to room temperature and anti-
bodies captured and removed. 200 μl of blocking buffer
(10% FBS in PBS) was added to each well and the plate
incubated at room temperature for 2 hours. The plate was
washed three times with PBS/Tween 20 (0.05%) (Sigma).
100 μl of standard or sample diluted in blocking buffer/
Tween 20 (0.05%) was added to each plate, which was
then sealed with parafilm and incubated at 4°C over-
night. The following day, the plate was washed four times
with PBS/Tween. 100 ul of the detection antibody, Goat
anti-human HGF antibody (Sigma), diluted to a concen-
tration of 0.01 μg/ml in blocking buffer/Tween 20, was
added to each well. After one hour incubation at room
temperature, and 4 washes with PBS/Tween 20, 100 μl of
avidin-horseradish peroxidase conjugated mouse anti-
goat IgG (Jackson ImmunoReseach) diluted 1:1000 in
blocking buffer/Tween 20 was added to each well. After
30 minutes incubation at room temperature and five
washes with PBS/Tween 20, 200 μl of Sigma Fast OPD
solution (Sigma) was added to each well. After 20 min-
utes, the plate was read at a wavelength of 405 nm using
a microplate reader (Molecular Devices, Sunnyvale, CA).
Data were analyzed using the Molecular Devices SOFT-
max program.
Cell migration
Cell migration assays were preformed according to prod-
uct instructions (CSM Inc. Phoenix, AZ). Chilled cell man-
ifolds were placed on Teflon-printed, precoated
microscope slides, subdivided into 10 wells, and filled
with ice-cold media. One μl of cell suspension (2500
cells) was added to each chamber and allowed to precipi-
tate by gravity and adhere to the coverslip. After two
hours, the manifold was moved to a cell incubator (37°C
under 5% CO2) and allowed to reach growth temperature
for 4 hours, at which point the cell sedimentation mani-
fold was removed and the coverslip submerged in media,
to which HGF was added. The area covered by cells was
recorded at 2 hrs and subsequently every 24 hours. The 2
hr area was used as a reference point for all succeeding
measurements. Results are presented as increases relative
to this area.
Protein sequencing of an HGF binding protein
The HGF and major co-immunoprecipitated product
from C4-2 cell lysates were excised from the gel and trans-
ferred to a siliconized tube, washed and destained in 50%
methanol overnight. The gel pieces were dehydrated in
aceto-nitrile, rehydrated in 10 mM dithiothreitol (DTT) in
0.1 M ammonium bicarbonate, and reduced at room tem-
perature for 30 minutes. The DTT solution was removed
and the samples alkylated in 50 mM iodoacetamide, in
0.1 M ammonium bicarbonate, for 30 minutes at room
temperature. Samples were then dehydrated again in
aceto-nitrile, rehydrated in 0.1 M ammonium bicarbo-
nate, dehydrated in aceto-nitrile and completely dried by
vacuum centrifugation. Finally, samples were rehydrated
for 10 minutes in 20 ng/ml trypsin in 50 mM ammonium
bicarbonate on ice. Any excess trypsin solution was
removed, and 50 mM ammonium bicarbonate added.
Samples were digested overnight at 37°C and the
sequences of generated peptides were identified by mass
specectrometry.
Cell lysis and Erk kinase assay
All cells were lysed in ice-cold lysis buffer (20 mMTris
PH7.4, 40 mM NaCl, 20 mM beta-glycerophosphate, 2
mM EGTA, 1 mM sodium orthovanadate, 2 mM DTT, 2
mM PMSF, 1μg/ml aprotinin, and 1μg/ml aprotinin). The
Map kinase assay was done with an assay kit (Upstate,
Lake Placid, NY). The kinase reaction was started by addi-
tion of kinase reaction buffer that contains 2 mg/ml
dephosphorylated myelin basic protein for each substrate,
20 mM MOPS (pH 7.2), 25 mM beta-Glycerophosphate,
5 mM EGTA, 0.4 mM MnCl2, 1 mM sodium orthovanad-
ate, 1 mM dithiothreitol, 75 mM MgCl2, and 500 μM ATP.
To prevent effects from other unknown kinases in the
lysate, 20 μM PKC inhibitor peptide, 2 μM PKA inhibitor
peptide, and 20 mM R24571 compound were added to
the kinase reaction buffer. The reaction was incubated for
20 min at 30°C, terminated by the addition of the LDS
sample buffer and loaded as aliquots for SDS-PAGE and
immunoblot analyses. Membrane enriched fractions were
purified as previously described [85].BMC Cancer 2006, 6:197 http://www.biomedcentral.com/1471-2407/6/197
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Immunoblot analyses
After centrifugation for 15 min at 15000 rpm in 4°C, the
lysate supernatant was collected. Protein concentration
was determined by BRC assay (BioRad, Hercules, CA).
Immunoblotting was performed using the NOVEX (Invit-
rogen, Carlsbad, CA) system. Briefly, 7.5 μg of cell extracts
and Erk kinase assay products were separated on 4–12%
Tris glycine PAGE gels and transferred onto a PVDF mem-
brane (Immoblin-P, Millipore, Billerica, MA). The mem-
brane was blocked 1 h at room temperature with TBST
blocking buffer [50 mM Tris-HCl (pH 8.0), 150 mM
NaCl, 0.05% Tween 20, and 5% nonfat milk]. The mem-
brane was incubated for 1 hr at room temperature with
primary anti-phosph MBP polyclonal antibody, anti-Erk
1,2 antibody, anti-PKB antibody, and anti-phosph PKB
antibody (Ser 473) in PBSN blocking buffer. A secondary
antibody (horseradish peroxidase-anti-rabbit or mouse
antibody) (Amersham Bioscience, Inc., Piscataway, NJ) at
a 1:5000 dilution was used in PBSN blocking buffer and
incubated for 1 hr at room temperature. ECL plus (Amer-
sham Bioscience, Inc.) reagent was used for detection.
Statistical analyses
Results were analyzed for statistical significance using the
nonparametric Mann-Whitney U test, with significance at
P < 0.05.
Results
HGF in stromal-conditioned media (SCM) regulates 
prostate cancer cell adhesive behaviors
Previously, our laboratory characterized cell responses to
media conditioned by primary prostate stromal cells, and
found differences between the responses of parental, non-
metastatic, human prostate LNCaP cells and those of its
lineage-derived, metastatic C4-2 subline [86]. Prostate
SCM collected in serum-free conditions had little effect on
LNCaP cells, but increased cell spreading of C4-2 cells on
laminin-1 substrates by 150–200% (Figure 1A) [68]. C4-
2 cells were not the only prostate cancer cells to respond
this way to SCM; cell spreading also increased following
SCM treatment of DU145 (brain metastatic human pros-
tate cell line), PC3, and PC3M (a bone metastatic human
prostate cell line of shared lineage). The SCM collected
from five different primary cultures and three different
hosts all had similar effects when incubated with C4-2
cells (data not shown). Many growth factors stimulate
focal adhesion assembly and influence integrin activity
[87], but we report here that these cell spreading effects of
SCM can be ameliorated by anti-HGF antibodies (Figure
1B). Thus, the HGF in the SCM is a major regulator of cell
adhesion and cell spreading.
To measure HGF amounts present in the SCM, we used
ELISA's and found HGF to range from 14 to 24 ng/ml
(Table 1). Cell spreading responses to HGF are concentra-
Prostate cancer cell lines compared for their cell spreading  responses to treatment with stromal cell-conditioned media  (SCM) Figure 1
Prostate cancer cell lines compared for their cell spreading 
responses to treatment with stromal cell-conditioned media 
(SCM). (A) All cell lines, except LNCaP, increased cell 
spreading on laminin, following exposure to the SCM. (B) 
C4-2 cell attachment to laminin, following treatment with 
SCM or purified HGF. Cells were allowed to attach for 90 
min., at which point ~25% of untreated C4-2 cells showed 
membrane protrusions. Induction of cell spreading, as seen 
for both SCM and purified HGF, is reversible by addition of 
anti-HGF antibody. Conditioned media from three primary 
stromal cell lines gave similar results (data not shown). 
Experimental cell spreading is shown as a percentage of con-
trol, untreated cells. Statistically significant differences from 
the control in each group were below P =< 0.05 (*). For each 
data point n = 6 or more.
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tion-dependent for both PC3 and C4-2 prostate cancer
cell lines, but an effective dose 50 (EC50) for PC3 cells is
achieved at a lower concentration (5 ng/ml) than for C4-
2 cells (30 ng/ml) (Figure 2A). These differences in maxi-
mal stimulation could be due to synergism between HGF
and other growth factors in the SCM, to the combined
presence of both met and nucleolin in PC3 cells, and/or
to differences in nucleolin and met affinities for HGF.
HGF-enhanced C4-2 cell spreading was substrate depend-
ent and observed only on laminin-1 (LM) substrate (Fig-
ure 2B), not on fibronectin (FN), collagen-1 (Col-1) or
vitronectin (VN). C4-2 cell spreading and cell migration
respond inversely to HGF treatment; that is, cell spreading
is enhanced, whereas cell locomotion is decreased on
laminin. The inhibitory effects of HGF on cell migration
were observed at 10 ng/ml (Figure 3A and 3B). Like the
cell spreading effects, migration inhibition was seen only
on a laminin-1 substrate, not on FN. HGF migration
responses could not be explained by cell proliferation,
because C4-2 cell cycle progression appeared unaffected
by HGF (data not shown). Furthermore, all cellular adhe-
sion could be block by either α6 or β1 integrin function
blocking antibodies and no changes in surface expression
of laminin binding integrins were observed (data not
shown).
HGF-induced cell adhesion and migration responses are 
mediated by Met-independent receptors
Using RT-PCR, we assess met expression levels in prostate
cancer cell lines of different metastatic potential (LNCaP,
C4-2, PC3 and DU145). Met receptor transcript (262 bp)
was present in DU145, PC3, PC3M and HeLa cells, but
absent or at very low levels in both LNCaP and C4-2 cells
(Figure 4A). These results were further confirmed by West-
ern blot analyses. Doublets of c-Met were observed, with
similar results for both the N-terminal and C-terminal
Met antibodies, used to check for possible Met isoforms
differing in their cytoplasmic tails (Figure 4B and 4C).
The HGF-Met signaling cascade is well described and
known to regulate invasion and metastasis, as well as cell
proliferation, survival, differentiation and branching mor-
phogenesis. Interactions between active HGF and Met
result in αβ heterodimer formation, trans-autophosphor-
ylation, and the recruitment of signaling intermediates
[21,33]. We searched for Akt and Erk phosphorylation in
both PC3 and C4-2 cells, and confirmed that C4-2 cells do
not respond to HGF with a functional Met signaling sys-
tem. Following HGF stimulation, Met is phosophorylated
Effect of HGF on cell spreading and matrix requirements Figure 2
Effect of HGF on cell spreading and matrix requirements. (A) 
Cell spreading behaviors on laminin substrata for PC3 and 
C4-2 cells exposed to variable concentrations of purified 
HGF. Because the cells differ in untreated attachment 
speeds, experiments were terminated at 30 minutes for PC3 
cells and 90 minutes for C4-2 cells. At these times, with high 
concentrations of HGF, filopodia and lamelipodia were visible 
in approximately 90% of PC3 cells and 65% of C4-2 cells. 
Both cell lines show a concentration-dependent increase in 
cell spreading. (B) HGF induction of C4-2 cell spreading is 
matrix-dependent, with spreading increasing only on laminin-
1 matrix (laminin, Fibronectin, Collagen I, and Vitronectin are 
LM, FN, CollI and VN, respectively). Experimental cell 
spreading is shown as a percentage of control, untreated 
cells. Statistically significant differences from the control in 
each group were below P =< 0.05 (*). For each data point n 
= 6 or more.
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Table 1: ELISA measurements of HGF concentrations in 
stromal-conditioned media from normal prostate stromal cells 
after 24 hr. culture
Stroma 1 18.5 (4.6)
Stroma 2 24.1 (2.3)
Stroma 3 16.4 (2.0)
Stroma 4 13.9 (1.5)
Stroma 5 22.6 (3.2)BMC Cancer 2006, 6:197 http://www.biomedcentral.com/1471-2407/6/197
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and activated only in PC3 cells, not C4-2 (Figure 5A and
5B). Furthermore, both Akt and Erk are activated in a
time-dependent manner in PC3 cells, but not in C4-2 cells
(Figure 5C). These findings disagree with a previous
report of a weak response to HGF, which may have been
due to activation of the PI3-kinase/Akt pathway by cell-
substrate adhesion that was further enhanced by HGF/SF
stimulation [88]. Our static stimulation of serum-starved
cells reveals clear enhancement of both Akt and Erk in
PC3, but not C4-2 cells. Since both RT-PCR and Western
blot were negative for met/Met in the LNCaP progression
model, their dose-dependent responses to HGF stimula-
tion suggest a Met-independent mechanism. This is fur-
ther shown by the activation of Rac upon HGF
stimulation in the C4-2 cells (Figure 5D and 5E).
Together, these results correlate well with our cell-spread-
ing and increased membrane ruffling data and further
argue for a Met-independent pathway for HGF response in
C4-2 cells.
Immunoprecipitation of PC3 and C4-2 total cell lysates
further confirms that Met is present in HGF-stimulated
PC3 cells and absent in C4-2 cells (Figure. 6A). HGF was
immobilized on agarose beads and incubated with cell
lysates. Immunoprecipitated product was then separated
and stained with an antibody against the Met cytoplasmic
domain. Control beads pulled down no detectable Met
protein from either PC3 or C4-2 lysates, as assayed by
both silver staining and immunoblotting (Figure 6A and
6B). Note that the silver-stained, immunoprecipitated
products of C4-2 cells contained two major bands of
approximately 60 kDa and 100 kDa. The lower band rep-
Expression of met in prostate cancer cell lines Figure 4
Expression of met in prostate cancer cell lines. (A) Met RT-
PCR detection of six transcripts in prostate cell lines. Ampli-
fied fragments of control μ-globulin and the cytoplasmic 
domain of human met are shown on an ethidium-bromide 
stained agarose gel. The length of the h-met PCR product 
was 262 bp. Product levels were close to undetectable in 
LNCaP and C4-2 samples. (B) Western blot analysis of total 
cell lysates from same prostate cell lines and HeLa cells. 
Equal amounts of cell lysate were separated and immunoblot-
ted with antibodies against either the extracellular (B) or 
cytoplasmic (C) domains of Met. Met was detected by char-
acteristic double bands in all cell lines except LNCaP and C4-
2.
500
400
300
200
A.
262 bp
L
N
C
a
P
C
4
-
2
D
U
1
4
5
P
C
3
P
C
3
-
M
H
e
L
a
μ-globulin
H
2
O
186
92
52
C.
C
4
-
2
P
C
3
L
N
C
a
P
P
C
3
-
M
D
U
1
4
5
H
e
L
a
Met
186
92
52
31
B.
C
4
-
2
P
C
3
L
N
C
a
P
P
C
3
-
M
D
U
1
4
5
H
e
L
a
Met
Time course and quantification of C4-2 migratory behaviors Figure 3
Time course and quantification of C4-2 migratory behaviors. 
C4-2 cells were plated in a defined circular area on laminin 
or fibronectin substrata, with different concentrations of 
HGF in the media. (A) Migration at 96 hr. time point, with 0 
or 100 ng/ml of HGF in the medium. (B) Time-dependent 
migration, in the presence of HGF, on different matrices. All 
values are normalized to the cell area at 0 hr. time point.
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(A, B) Immunoprecipitation of Met in C4-2 and PC3 with and without activation by HGF Figure 5
(A, B) Immunoprecipitation of Met in C4-2 and PC3 with and without activation by HGF. (C) Time-dependent activation of 
both Erk and Akt is visible in PC3 cells but not C4-2. (D, E) Rac is activated but not cdc42 upon HGF stimulation in C4-2 cells, 
as seen by immunoprecipitation of active GTPases.
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Precipitation of HGF binding proteins from C4-2 and PC3 cells, using beads coated with HGF or BSA Figure 6
Precipitation of HGF binding proteins from C4-2 and PC3 cells, using beads coated with HGF or BSA. (A) Met was precipitated 
in the PC3 cell line, while (B) in the C4-2 cell line two bands were precipitated using HGF coated beads but not with BSA con-
trol beads. The lower major band is HGF itself; the upper 100 kDa band was purified and sequenced. Western-blot analyses 
(C) and sequencing of the upper band confirmed it to be nucleolin (see table 2). (D) The importance of nucleolin to HGF-stim-
ulated spreading on laminin substrata was apparent when antibodies to nucleolin reduced the effect of HGF (E). The cell 
spreading behaviors were quantified and presented as the mean of triplicate experiments. Statistically significant differences 
from the control were at P =< 0.005 (*).
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resents HGF itself, as identified by Western blot (data not
shown), whereas the higher band was micro-sequenced
and identified as nucleolin, with an expected size of 98
kDa (Table 2).
Nucleolin is an HGF binding partner in the C4-2 prostate 
cancer cell line
Of the 98 kDa band isolated from total C4-2 cell lysates
(by columns of HGF-coated agarose beads), a total of 24
peptides were sequenced, corresponding to approxi-
mately 30% of the protein sequence of nucleolin, with
100% identity match to the previously published protein
sequence (NCBI#4885511; Table 2). The identity of the
100 kDa protein was further confirmed by Western blot-
ting to nucleolin (Figure. 6C). No other sequence homol-
ogies were found, suggesting that nucleolin is the major
protein in the 100 kDa band, and that nucleolin is the
major binding partner for HGF in C4-2 cells. Most com-
pellingly, antibodies against nucleolin were able to block
the cell spreading phenotype observed in HGF-treated
cells in our cell attachment assay system (Figure 6D and
6E); in other words, Met-negative C4-2 cells increased cell
spreading behavior when treated with HGF, and this
response could be abolished by the addition of antibodies
against the nucleolin protein (or HGF or specific integrin
subunits, data not shown). Although we do not see any
changes in the total nucleolin expression levels in the
cells, we do see an increase in the membrane-associated
nucleolin in both the LNCaP and PC3 progression models
(Figure 7). This strengthens the link between nucleolin
and HGF function, at the same time that it argues for cell
surface localization of the nucleolin protein during cancer
progression.
Discussion
We have used prostate cancer cell lines and stromal-con-
ditioned media to study the regulatory interplay between
prostate epithelial and stromal cells during prostate can-
cer progression, and have now begun to tease apart the
Nucleolin and Met expression profiles during disease pro- gression, as modeled across LNCaP and PC3 prostate cancer  cell lines Figure 7
Nucleolin and Met expression profiles during disease pro-
gression, as modeled across LNCaP and PC3 prostate cancer 
cell lines. (A) Comparison of protein levels in total cell lysate 
and plasma membrane fractions by Western blotting. (B) 
Normalizing membrane nucleolin levels to levels in the less-
advanced parental cell lines of each progression model, 
reveals that membrane nucleolin levels are higher than 
parental in both C4-2 and PC3M. Nucleolin levels were 30% 
higher in prostate parental cells compared to normal (p69 
and RWPE-2) prostate epithelial cells (data not shown).
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Table 2: 24 peptides were sequenced from cell lysates, based on 
co-immunoprecipitation with purified HGF protein. All peptides 
showed 100% sequence homology to previously cloned nucleolin 
(NCBI#4885511). Numbers within the Table refer to the 
peptide's location within the published nucleolin sequence.
72–79 VAVATPAK
72–80 VAVATPAKK
296–318 QKVEGTEPTTAFNLFVGNLNFNK
325–333 TGISDVFAK
334–342 NDLAVVDVR
348–362 KEGYVDFESAEDLEK
349–362 FGYVDFESAEDLEK
363–370 ALELTGLK
404–410 VTQDELK
404–420 VTQDELKEVFEDAAEIR
411–420 EVFEDAAEIR
428–437 SKGIAYIEFK
430–437 GIAYIEFK
438–449 TEADAEKTFEEK
450–457 QGTEIDGR
458–467 SISLYYTGEK
478–486 NSTWSGESK
522–537 SKGYAFIEFASFEDAK
525–537 GYAFIEFASFEDAK
555–561 LELQGPR
578–597 GLSEDTTEETLKESFDGSVR
611–624 GFGFVDFNSEEDAK
625–636 EAMEDGEIDGNK
625–645 EAMEDGEIDGNKVTLDWAKPKBMC Cancer 2006, 6:197 http://www.biomedcentral.com/1471-2407/6/197
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relationships between stromally-derived HGF signal, Met
signal reception, integrin-based cell adhesive responses,
and a new HGF binding partner, the nucleolin protein.
We report here: 1) that it is the HGF in stromal-condi-
tioned media that affects C4-2 metastatic prostate cancer
cell adhesive behavior, 2) that this action is through the
integrins, and 3) that the dose-dependent response of
Met-negative C4-2 cells to HGF treatment can be abol-
ished through the addition of antibodies against the
nucleolin protein.
HGF response without Met and with nucleolin
A Met-independent pathway acting in the absence of Met
and/or alongside Met could increase the variety of possi-
ble cell responses to HGF. Classically, the binding of HGF
to Met induces receptor dimerization and phosphoryla-
tion of two conserved tyrosine sites; when these sites are
mutated, mice show similar phenotypes to those with
HGF or Met knockouts [89]. But C4-2 cells, which lack
this signaling pair, could be revealing spreading behaviors
due to low-affinity HGF sites that allow response to higher
levels of HGF (compared to Met-expressing PC3 cells; Fig-
ure 2). Past research on HGF affinity has identified some
binding sites in hepatocytes with 10-fold lower affinity
[90]. HGF interactions with proteoglycans and CD44 is
linked to enhanced Met signaling and possible Met auto-
phosphorylation [91,92]. Pollack et al. [93] suggest that in
Madin Darby canine kidney (MDCK) cells, low-affinity
binding of HGF in the presence of the Met receptor may
alter downstream responses. Thus, we are certainly not the
first to suggest either additional HGF receptors, or HGF
binding to heparin and oligosaccharide signaling systems
[94,95]. Our study is unique, however, in our identifica-
tion of the HGF binding partner nucleolin.
Nucleolin, originally called C23 [96], was first character-
ized as an abundant nuclear protein with a role in ribos-
ome biogenesis [69,70]. Because nucleolin synthesis
correlates positively with cell growth, the especially high
expression of nucleolin in tumor cells is not surprising
[97]. Nucleolin is further a major regulatory and phos-
phorylation target following androgen treatment [98,99].
Nucleolin's  in vivo localization to the cell surface in
aggressive tumor cells [77,78,99,100] agrees with our in
vitro finding of membrane localization in both LNCaP
and PC3 progression model cell lines (Figure 7). This
membrane localization has recently generated interest in
the use of nucleolin as a tumor marker and therapeutic
target. A nucleolin functional inhibitor called AGRO100
(a guanine-rich oligonucletide) has been successful in
Phase I clinical trials, and Phase II trials are underway
[77,78,101]. Further evidence of nucleolin's role in cancer
progression comes from our unrelated, in vivo bio-pan-
ning study. While bio-panning with a 12-mer peptide
phage-display library, a peptide (designated L13) was
found to bind with high specificity to murine bone mar-
row. When human bone marrow endothelial cell lysates
were passed across an L13 column, the major species
eluted was found to be nucleolin ([102]and unpublished
observations). Indeed, a tumor homing peptide, F3, that
binds specifically to tumor endothelial cells was described
by Christian et al. [75] as interacting directly with nucleo-
lin. Together, there is now clear evidence of nucleolin's
involvement in cancer cell behavior and response to HGF,
although this protein's direct and/or indirect functions
remain to be discovered.
Nucleolin on the cell surface
Nucleolin is named for the fact that it makes up as much
as 10% of the total nucleolar protein [103], but it also
functions as a shuttle protein between the cytoplasm and
the nucleus, is found in clusters associated with the actin
cytoskeleton [104-106], and is sensitive to cytochalasin D
[104]. Nucleolin is present on the cell surfaces of a variety
of cell types [71,107,108], and surface-expressed nucleo-
lin appears to interact with an array of other proteins,
including viral proteins during infections [109,110], βFGF
and Midkine [111], and laminin-1 [112,113].
A three-way interaction between nucleolin, HGF, and
integrins is suggested by our ability, in short-term assays,
to inhibit HGF's cell spreading effects using anti-nucleolin
antibodies (Figure 6D); Nucleolin inhibition, alone, how-
ever, in the absence of HGF stimulation, does not alter
C4-2 laminin adhesion (data not shown). Also, nucleolin
by itself is not able to sustain laminin adhesion, as we
were able to completely block cell spreading under stimu-
lated and un-stimulated conditions, using function-block-
ing antibodies to either β1 or α6 integrin (data not shown).
Yu et al. [114] studied the cellular distribution of nucleo-
lin after stimulation with ECM proteins, and report that,
following laminin stimulation, nucleolin translocates
from the cytoplasm to the nucleus and stimulates cell pro-
liferation. Following HGF stimulation, we do not detect
changes in laminin-binding integrin expression profiles
(data not shown), but we have previously seen changes in
integrin function (not expression) in these same prostate
cells [68]. Also possible is the movement of additional
nucleolin protein to the cell surface, providing direct
increase in laminin adhesion [72,112,114]. Nucleolin
may function as a generic GF-HS binding receptor, linking
HGF and integrin function. Like syndecan, nucleolin has
been found to bind HGF's heparin-binding domain,
thereby sequestering HGF on the cell surface. In our stud-
ies, nucleolin does not co-immunoprecipitate with other
heparin-binding growth factors (data not shown), but
HGF-Nucleolin interactions do respond to heparin com-
petition (data not shown). We are currently searching for
other components in nucleolin-HGF interactions using
BIAcore. The findings we report here, together with theBMC Cancer 2006, 6:197 http://www.biomedcentral.com/1471-2407/6/197
Page 12 of 15
(page number not for citation purposes)
nucleolin-focused independent clinical trial underway
[77,78], introduce nucleolin as an attractive target for
therapeutic regulation of prostate cancer, although the
details of its position in cancer cell HGF signaling remain
to be found.
Additional components in HGF/nucleolin interactions
We sought to begin placing nucleolin in or beside well-
described HGF-met signaling pathways affecting integrin-
based cell behaviors. Cell spreading and membrane ruf-
fling behaviors seen in C4-2's met-independent HGF cell
responses led us to look first at small GTPases (Figure 5).
We found that Rac is activated by HGF treatment of met-
negative C4-2 cells (Figure 5D,E). Rho, Rac and cdc42 are
part of the Ras small GTPase superfamily, and play key
roles in regulating cell shape, contraction, adhesion,
motility, and proliferation [115-117]. Members of this
GTPase superfamily are also known molecular triggers to
response cascades following growth factor stimulation
([118] and references within). Rac, in particular is a regu-
lator of the superoxide generating NADPH oxidase in
phagocytes [119]. The production of reactive oxygen spe-
cies (ROS) mediates activation of NF-κB-dependent gene
expression, essential for tumorigenesis and metastasis.
Conclusion
We have found evidence that HGF secreted by prostate
stromal cells regulates prostate cancer cell adhesive behav-
iors, even in cells that lack Met, the one known HGF
receptor. Further, we report that the nucleolin protein
expressed on the surfaces of these prostate cancer cells (in
increasing levels during disease progression) is involved
in the HGF regulatory interplay between stromal and epi-
thelial cells within the prostate, and possibly also at sites
of metastasis. A family of drugs targeting the nucleolin
protein are being developed for cancer therapy; these
AGRO100 drugs (named for Guanine-Rich Oligonucle-
otides) reportedly acted against cultured cell lines from
several different cancers and successfully stabilized dis-
ease in six of nine patients in phase I clinical trials. They
are now in phase II trials [77,78]. We have independently
identified nucleolin protein as having a role in cancer pro-
gression, and have now linked nucleolin's function to
prostate cancer cell reception of Hepatocyte Growth Fac-
tor (HGF) and integrin-based cell adhesive behaviors.
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